The antiserum was produced against synthesized peptide derived from human A-RAF around the phosphorylation site of Ser299. AA range:266-315

Phospho-A-Raf (S299) Polyclonal Antibody detects endogenous levels of A-Raf protein only when phosphorylated at S299.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):RDsGY

ARAF

Serine/threonine-protein kinase A-Raf

ARAF ;
ARAF1 ;
PKS ;
PKS2 ;
Serine/threonine-protein kinase A-Raf ;
Proto-oncogene A-Raf ;
Proto-oncogene A-Raf-1 ;
Proto-oncogene Pks

This proto-oncogene belongs to the RAF subfamily of the Ser/Thr protein kinase family, and maybe involved in cell growth and development. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Jan 2012],

Catalytic activity:ATP + a protein = ADP + a phosphoprotein.,cofactor:Binds 2 zinc ions per subunit.,Function:Involved in the transduction of mitogenic signals from the cell membrane to the nucleus.,similarity:Belongs to the protein kinase superfamily.,similarity:Belongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family. RAF subfamily.,similarity:Contains 1 phorbol-ester/DAG-type zinc finger.,similarity:Contains 1 protein kinase domain.,similarity:Contains 1 RBD (Ras-binding) domain.,subunit:Interacts with TH1L/NELFD.,tissue specificity:Predominantly in urogenital tissues.,

intracellular,mitochondrion,cytosol,

Predominantly in urogenital tissues.

>>EGFR tyrosine kinase inhibitor resistance ;
>>Endocrine resistance ;
>>MAPK signaling pathway ;
>>ErbB signaling pathway ;
>>FoxO signaling pathway ;
>>Vascular smooth muscle contraction ;
>>Natural killer cell mediated cytotoxicity ;
>>Long-term potentiation ;
>>Serotonergic synapse ;
>>Long-term depression ;
>>Regulation of actin cytoskeleton ;
>>Insulin signaling pathway ;
>>Progesterone-mediated oocyte maturation ;
>>Parathyroid hormone synthesis, secretion and action ;
>>Alzheimer disease ;
>>Pathways of neurodegeneration - multiple diseases ;
>>Alcoholism ;
>>Hepatitis C ;
>>Hepatitis B ;
>>Pathways in cancer ;
>>Proteoglycans in cancer ;
>>Chemical carcinogenesis - reactive oxygen species ;
>>Colorectal cancer ;
>>Renal cell carcinoma ;
>>Pancreatic cancer ;
>>Endometrial cancer ;
>>Glioma ;
>>Prostate cancer ;
>>Melanoma ;
>>Bladder cancer ;
>>Chronic myeloid leukemia ;
>>Acute myeloid leukemia ;
>>Non-small cell lung cancer ;
>>Breast cancer ;
>>Hepatocellular carcinoma ;
>>Gastric cancer